https://www.thebodypro.com/category/meeting-costs-hiv-care/tag/hepatitis-c

The Latest

close up of man's arm getting blood drawn

We Have a Cure for Hepatitis C. Why Are Rates So High?

An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).

Promo Image

This Week in HIV Research: Do We Need New Statin Guidelines?

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

The DMV Balenciaga House Meeting

With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing

The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.

Kids With Hepatitis C Get New Drugs and Coverage May Prove Easier Than for Adults Img

Kids With Hepatitis C Get New Drugs and Coverage May Prove Easier Than for Adults

With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure.

Powerful Hepatitis C Notice From U.S. Government Will Expand Access to High Cost Meds Img

Powerful Hepatitis C Notice From U.S. Government Will Expand Access to High Cost Meds

A letter from the Obama Administration tells states that Medicaid must allow more people to get costly drugs that can cure their hep C, sending a strong messages for HIV and other diseases with high cost meds.

Sofosbuvir Access: New Patent Challenges to Sofosbuvir Img

Sofosbuvir Access: New Patent Challenges to Sofosbuvir

The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.

Money Trail: Some Guidance for the Journey Img

In the Golden Age of the Hep C Cure, Discount Deals Tie Doctors' Hands

Who has the power to prescribe medications? In the ongoing struggle to cure the estimated 3.2 million people living with chronic hepatitis C virus (HCV) infection in the U.S., the answer may not be who you think.

The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies Img

The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies

Gilead has devised a strategy to extract maximum profits, suggests policy analyst Brook Baker. He urges us not to blame governments and force taxpayers to create more pharmaceutical wealth, and instead calls for action to ensure access for all at an ...

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...